Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 15, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 680,000 ordinary shares of 25 pence each.
- Purchase Price: 1,463.1505 pence per share.
- Treasury Holdings: 172,906,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,809,629,396 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 680,000 shares on June 15, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 680,000 shares by the price of 1,463.1505 pence.
- Confirm the updated total share count (5,809,629,396 in issue) against subsequent filings to track dilution or further buybacks.
- Note that this filing is a notification of a specific transaction and does not replace quarterly or annual financial reports.